Navigation Links
BioLife Solutions Adds Clinical and Commercialization Experts to Scientific Advisory Board
Date:1/23/2012

BOTHELL, Wash., Jan. 23, 2012 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer, manufacturer, and marketer of proprietary hypothermic storage and cryopreservation freeze media for cells,  tissues, and organs, today announced that three additional key opinion leaders in the biobanking, drug discovery, and regenerative medicine markets have joined the Company's Scientific Advisory Board (SAB). The new members are:

  • Edward LeCluyse, Ph.D., Senior Research Investigator at The Hamner Institutes for Health Sciences. Dr. LeCluyse pioneered the use of HypoThermosol® and CryoStor® in improving preservation of research designated livers and derived commercial hepatocytes marketed to the pharmaceutical industry.
  • John McMannis, Ph.D., Executive Vice President of Manufacturing at Mesoblast Limited. Dr. McMannis was previously the Director, Cellular Therapy Laboratory, Department of Stem Cell Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Jon Rowley, Ph.D., Innovation Director of Cell Processing Technologies at Lonza Biosciences, responsible for driving technology development and innovation related to commercial scale bioprocessing of therapeutic cell-based products.
  • Mike Rice, BioLife Chief Executive Officer, commented on the expansion of BioLife's SAB by stating, "We're thrilled that Drs. LeCluyse, McMannis, and Rowley have joined our Scientific Advisory Board.  Each is a very highly thought of opinion leader in their respective fields.  We look forward to their contributions to our strategies for continually improving our quality environment and products and services offering."

    These new members join the founding members of BioLife's SAB, who are:

  • Scott M. Burger, M.D., principal of Advanced Cell and Gene Therapy, a consulting firm specializing in cell, gene, and tissue-based therapies.
  • Lizabeth J. Cardwell, MT (ASCP), MBA, RAC, Compliance Consulting for Cell Therapy and Biotechnology. Ms. Cardwell has provided Quality Assurance and Regulatory consulting for start-up cell therapy and biotechnology companies since 2005. Prior to August 2005, Ms. Cardwell held the position of Director of Regulatory Affairs and Quality Assurance at Xcyte Therapies.
  • Colleen Delaney, M.D., is the Director of the Cord Blood Research and Transplant Program at Fred Hutchinson Cancer Research Center (FHCRC) and Seattle Cancer Care Alliance (SCCA). She is an attending physician at Seattle Children's Hospital, Assistant Member of the Clinical Research Division of FHCRC and Assistant Professor at the University of Washington School of Medicine.
  • Dayong Gao, Ph.D., professor of biomedical engineering at the University of Washington in Seattle. Dr. Gao has been actively engaged in cryopreservation research for more than 20 years, having authored over 130 peer-reviewed journal articles on cryopreservation.
  • Shelly Heimfeld, Ph.D., is the Director, Heimfeld Research Laboratory, Scientific Director, Cellular Therapy Laboratory, and Scientific Director, cGMP Therapeutic Manufacturing Facilities at the Fred Hutchinson Cancer Research Center. Dr. Heimfeld is internationally recognized for research in hematopoietic-derived stem cells and the development of cell processing technologies for improved cancer therapy.
  • Andrew Hinson joined the Board in February 2007. He is currently the Vice President for Clinical and Regulatory Affairs for LoneStar Heart, Inc., a developer of proprietary biopolymer, small molecule and cellular-based therapies to effectively treat heart failure and other cardiac conditions. Mr. Hinson has diverse experience in the cell and gene therapy markets and extensive experience with regulatory and clinical trial issues for new therapies for cardiac, neurologic, and gastrointestinal applications.
  • Darin Weber, Ph.D., is a leading regulatory expert for cellular and tissue based products, and a former FDA cellular therapy reviewer. He is currently the Executive Vice President, Global Regulatory Affairs at Mesoblast Limited. Dr. Weber's knowledge of the regulatory landscape for cell and gene therapy is extensive and directly relevant to the Company's business since its biopreservation media products are a critical process component in numerous active clinical trials for new cellular therapy products.
  • Erik J. Woods, Ph.D.,Co-Founder, CEO of General Biotechnology, LLC, and Laboratory Director of The Genesis Bank, a private umbilical cord blood bank. Dr. Woods is the current president of the Society for Cryobiology.
  • (Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

    About BioLife SolutionsBioLife Solutions develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs.  The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are marketed to academic and commercial organizations involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced, delayed-onset cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvements in post-thaw cell, tissue, and organ viability and function.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

    This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.  These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact.  Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission.  BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.  Media Relations:Investor Relations: Len Hall

    Matt Clawson

     Allen & Caron Inc

    Allen & Caron Inc

     (949) 474-4300

    (949) 474-4300

     len@allencaron.com

    matt@allencaron.com

      

     

     


    '/>"/>

    SOURCE BioLife Solutions, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related biology technology :

    1. BioLife Solutions 2011 Revenue Up 33%
    2. BioLife Solutions Launches Search Engine Optimized Website and 1,000 Free Samples Offer
    3. BioLife Solutions Now The Leading Supplier of Pre-Formulated GMP Cryopreservation Media for Umbilical Cord Blood Stem Cells
    4. BioLife Solutions CEO Issues 2010 Corporate Update
    5. BioLife Solutions Achieves ISO 13485 Quality Management Systems Certification
    6. BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement
    7. BioLife Solutions Granted Japanese Biopreservation Patent
    8. BioLife Solutions Announces HypoThermosol(R) and CryoStor(TM) Distribution Agreement With Sigma-Aldrich
    9. BloodStor(TM) Stem Cell Biopreservation Media Platform Launched by BioLife Solutions
    10. BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement
    11. BioLife Solutions Announces Validation and Start-Up of New Internal Manufacturing Facility for Serum-Free Cell and Tissue Biopreservation Media Products
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/21/2017)... ... February 21, 2017 , ... Creation ... manufacturing solutions for original equipment manufacturers (OEMs) , today announced it has received ... third consecutive year winning in its category of electronics manufacturing services (EMS) providers ...
    (Date:2/21/2017)... , Feb. 21, 2017  Lexus, a returning partner of the ... the official and exclusive automobile partner of the men,s and women,s ... The 2017 Amgen Tour of California ... feature some of the best professional cycling teams in the world ... 14-20. The four-day Amgen Breakaway from Heart Disease TM ...
    (Date:2/21/2017)... 2017 Scientists From Two Companies ... Plastic Industry  ... STEER, creator of advanced materials platform ... fields of plastics, pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, ... science & technology company, on creating co-rotating twin screw ...
    (Date:2/21/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Bioplastics & Biopolymers ... over the next decade to reach approximately $8.9 billion by 2025. ... forecasts for all the given segments on global as well as ...
    Breaking Biology Technology:
    (Date:2/16/2017)... 2017  Genos, a community for personal genetic ... received Laboratory Accreditation from the College of American ... laboratories that meet stringent requirements around quality, accuracy ... "Genos is committed to maintaining the ... honored to be receiving CAP accreditation," said ...
    (Date:2/9/2017)... 9, 2017 The biomass boiler market report ... biomass boiler market globally in terms of revenue (US$ ... The market for biomass boilers has been segmented on ... and country/region. The market based on feedstock type, has ... biogas & energy crops, urban residues, and others. On ...
    (Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... billion by 2021 from $8.3 billion in 2016 at ... 2016 to 2021. Report Includes - An overview ... global market trends, with data from 2015 and 2016, ... 2021. - Segmentation of the market on the basis ...
    Breaking Biology News(10 mins):